Journal
ACTA PHARMACOLOGICA SINICA
Volume 30, Issue 9, Pages 1316-1322Publisher
ACTA PHARMACOLOGICA SINICA
DOI: 10.1038/aps.2009.119
Keywords
rosiglitazone; hepatocellular carcinoma; PTEN; PPAR gamma; 5-fluorouracil
Funding
- National Natural Science Foundation of China [30672053]
- Guangdong Natural Science Foundation [9451018201003643]
- Doctoral start-up funds of Guangzhou Medical College [2008C35]
Ask authors/readers for more resources
Aim: Resistance to 5-fluorouracil (5-FU) is a major cause of chemotherapy failure in advanced hepatocellular carcinoma (HCC). Rosiglitazone, a peroxisome proliferator-activated receptor gamma (PPAR gamma) agonist, has a crucial role in growth inhibition and induction of apoptosis in several carcinoma cell lines. In this study, we examine rosiglitazone-induced sensitization of HCC cell lines (BEL-7402 and Huh-7 cells) to 5-FU. Methods: The 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) assay was used to evaluate cell viability. Western blotting analysis was performed to detect the protein expression (PPAR gamma, PTEN, and COX-2) in BEL-7402 cells. Immunohistochemistry staining was used to examine the expression of PTEN in 100 advanced HCC tissues and paracancerous tissues. In addition, small interfering RNA was used to suppress PPAR., PTEN, and COX-2 expression. Results: Rosiglitazone facilitates the anti-tumor effect of 5-FU in HCC cell lines, which is mediated by the PPAR. signaling pathway. Activation of PPAR. by rosiglitazone increases PTEN expression and decreases COX-2 expression. Since distribution of PTEN in HCC tissues is significantly decreased compared with the paracancerous tissue, over-expression of PTEN by rosiglitazone enhances 5-FU-inhibited cell growth of HCC. Moreover, down-regulation of COX-2 is implicated in the synergistic effect of 5-FU. Conclusion: Rosiglitazone sensitizes hepatocellular carcinoma cell lines to 5-FU antitumor activity through the activation of PPAR gamma. The results suggest potential novel therapies for the treatment of advanced liver cancer.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available